Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 15 de 15
Filtrar
1.
Arch Oral Biol ; 120: 104923, 2020 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-33091661

RESUMO

OBJECTIVES: Bone resorption associated to chronic diseases, such as arthritis and periodontitis, results from exacerbated immuno-inflammatory host response that leads to tissue breakdown. The significance of opioid pathways as endogenous modulators of inflammatory events has already been described. Thus, the aim of this work is to determine whether some of the main three opioid receptors are endogenously activated to prevent bone loss during experimentally-induced alveolar bone resorption. DESIGN: This study used an experimental model of alveolar bone resorption induced by ligature in rats. A silk thread was placed around the 2nd maxillary molar of male Wistar rats. In the 3rd, 4th and 5th day after ligation the rats received a local injection of different concentrations of opioid antagonists Cyprodime, Naltrindole, or Nor-binaltorphimine, which specifically block mü, delta and kappa opioid receptors, respectively. In the 7th experimental day, rats were euthanized and their maxillae collected for evaluation of alveolar bone and fiber attachment loss, morphometric counting of osteoclasts and osteoblasts, as well as the levels of cytokines IL-1ß, IFN-γ, and IL-6 by ELISA. RESULTS: Selective antagonism of kappa opioid receptors, but not mü and delta, exacerbated alveolar bone resorption induced by ligature in rats. The increased bone loss associated with higher number of osteoclasts surrounding alveolar bone, although osteoblasts' counting remained unchanged. The concentrations of IL-1ß and IL-6 in periodontal tissues were also significantly higher in the rats treated with the kappa antagonist. CONCLUSION: Inhibiting kappa opioid receptors exacerbates alveolar bone resorption.


Assuntos
Perda do Osso Alveolar , Reabsorção Óssea , Antagonistas de Entorpecentes/efeitos adversos , Periodontite , Receptores Opioides , Animais , Citocinas , Modelos Animais de Doenças , Masculino , Morfinanos , Naltrexona/análogos & derivados , Osteoblastos , Osteoclastos , Ratos , Ratos Wistar
2.
J Biomater Appl ; 35(3): 405-421, 2020 09.
Artigo em Inglês | MEDLINE | ID: mdl-32571173

RESUMO

Although, the excellent level of success of titanium surfaces is based on the literature, there are some biological challenges such as unfavorable metabolic conditions or regions of poor bone quality where greater surface bioactivity is desired. Seeking better performance, we hypothesized that silica-based coating via sol-gel route with immersion in potassium hydroxide basic solution induces acceleration of bone mineralization. This in vitro experimental study coated titanium surfaces with bioactive glass synthesized by route sol-gel via hydrolysis and condensation of chemical alkoxide precursor, tetraethylorthosilicate (TEOS) and/or deposition of chemical compound potassium hydroxide (KOH) to accelerate bone apposition. The generated surfaces titanium(T), titanium with potassium hydroxide deposition (T + KOH), titanium with bioactive glass deposition synthesized by sol-gel route via tetraethylorthosilicate hydrolysis (TEOS), titanium with bioactive glass deposition synthesized by sol-gel route via tetraethylorthosilicate hydrolysis with potassium hydroxide deposition (TEOS + KOH) were characterized by 3D optical profilometry, scanning electron microscopy (SEM), transmission electron microscopy (TEM), contact angle by the sessile drop method, x-ray excited photoelectron spectroscopy (XPS) and energy dispersive x-ray spectrometer (EDX). The addition of the KOH group on the pure titanium (T) or bioactive glass (TEOS) surfaces generated a tendency for better results for mineralization. Groups covered with bioactive glass (TEOS, TEOS + KOH) tended to outperform even groups with titanium substrate (T, T + KOH). The addition of both, bioactive glass and KOH, in a single pure titanium substrate yielded the best results for the mineralization process.


Assuntos
Materiais Revestidos Biocompatíveis/química , Géis/química , Hidróxidos/química , Compostos de Potássio/química , Dióxido de Silício/química , Titânio/química , Animais , Calcificação Fisiológica , Adesão Celular , Proliferação de Células , Materiais Revestidos Biocompatíveis/metabolismo , Implantação Dentária , Humanos , Camundongos , Osteogênese , Silanos/química , Propriedades de Superfície , Titânio/metabolismo
3.
Rev. odontol. Univ. Cid. São Paulo (Online) ; 29(3): [243-246], set-dez. 2017.
Artigo em Português | LILACS, BBO - Odontologia | ID: biblio-908735

RESUMO

Existe uma relação importante entre o estado de saúde bucal e aquele da saúde geral. Em pacientes hospitalizados essa relação assume importância ainda maior, pois o indivíduo encontra-se fragilizado e, muitas vezes, é incapaz de realizar uma higiene bucal adequada. O presente trabalho trata-se de uma revisão de literatura que tem como objetivo discutir os principais problemas bucais apresentados por pacientes hospitalizados, principalmente aqueles que ficam por longo período de tempo. A maioria dos trabalhos encontrados relata que a saúde bucal de pacientes hospitalizados por longos períodos é precária e que isso afeta diretamente a saúde geral dos mesmos. Concluiu-se que uma saúde bucal adequada pode melhorar a resposta do paciente ao tratamento médico e que a presença de cirurgiões dentistas nas equipes multiprofissionais dos hospitais é de extrema importância para a implementação de protocolos clínicos de conduta visando tanto a prevenção quanto a recuperação da saúde bucal dos pacientes hospitalizados


There is an important relationship between the state of oral health and that of overall health. In hospitalized patients this relationship is even more important because the individual is debilitated and,most of the time, is unable to perform an adequate oral hygiene. This work is a literature review that aims to discuss the main oral problems presented by hospitalized patients, especially those who stay for longer period of time. Most studies found that the oral health of hospitalized patients for long periods is precarious and that this directly affects the overall health of them. It leads to the conclusion that adequate oral health can improve a patient's response to medical treatment and that the presence of dentists in multidisciplinary teams of hospitals is of extreme importance for the implementation of clinical management protocols aimed at both prevention and recovery of oral health of hospitalized patients


Assuntos
Unidade Hospitalar de Odontologia , Saúde Bucal , Pacientes Internados , Unidades de Terapia Intensiva
4.
Eur J Pharmacol ; 713(1-3): 1-5, 2013 Aug 05.
Artigo em Inglês | MEDLINE | ID: mdl-23665491

RESUMO

Angiotensin II (Ang II) may be produced directly from angiotensinogen by tonin. Studies have demonstrated that Ang II and its metabolite Ang-(1-7) produce antinociception in pain animal models. The aim of the present study was to determine whether the transgenic mice that express rat tonin (TGM(rTon)) show altered nociceptive behavior and investigate the possible involvement of angiotensin metabolites. Nociception was evaluated using the thermal tail-flick and chemical acetic acid writhing tests, and the drugs were administered by intracerebroventricular and subcutaneous pathways, respectively. Probabilities less than 5% (P<0.05) were considered to be statistically significant (t test; ANOVA/Bonferroni's test). The results demonstrate that the transgenic mice showed an antinociceptive effect in the tail-flick and acetic acid writhing tests. In addition, it was observed that losartan, an AT1 receptor antagonist and A-779 (D-Ala7-Ang-(1-7)), a Mas receptor antagonist attenuated the antinociceptive behavior. Our data suggest that the Ang II produced in TGM(rTon) induces antinociception via the AT1 receptor, while the Ang-(1-7) produced from Ang II induced antinociception via the Mas receptor.


Assuntos
Angiotensina II/metabolismo , Nociceptividade/fisiologia , Dor Nociceptiva/metabolismo , Calicreínas Teciduais/metabolismo , Angiotensina I/metabolismo , Angiotensina II/análogos & derivados , Angiotensina II/farmacologia , Bloqueadores do Receptor Tipo 1 de Angiotensina II/farmacologia , Animais , Comportamento Animal/efeitos dos fármacos , Comportamento Animal/fisiologia , Modelos Animais de Doenças , Losartan/farmacologia , Masculino , Camundongos , Camundongos Transgênicos , Nociceptividade/efeitos dos fármacos , Medição da Dor , Fragmentos de Peptídeos/metabolismo , Fragmentos de Peptídeos/farmacologia , Ratos , Receptores Acoplados a Proteínas G/antagonistas & inibidores , Calicreínas Teciduais/genética
5.
J Pharm Pharmacol ; 64(8): 1084-9, 2012 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-22775211

RESUMO

OBJECTIVES: The aim of this study was to determine whether Ca(2+)-activated Cl(-) channels (CaCCs) are involved in central antinociception induced by the activation of µ-, δ- and κ-opioid receptors. METHODS: The nociceptive threshold for thermal stimulation was measured using the tail-flick test in Swiss mice. The drugs were administered via the intracerebroventricular route. Probabilities values of P < 0.05 were considered to be statistically significant (analysis of variance/Bonferroni test). KEY FINDINGS: The results demonstrate that exposure to the CaCC blocker niflumic acid (2, 4 and 8 µg) partially reverses the central antinociception induced by the δ-opioid receptor agonist SNC80 ((+)-4-[(αR)-α-((2S,5R)-4-allyl-2,5-dimethyl-1-piperazinyl)-3-methoxybenzyl]-N,N-diethylbenzamide; 4 µg). In contrast, niflumic acid did not modify the antinociceptive effect of the µ-opioid receptor agonist [D-Ala(2), N-Me-Phe(4), Gly(5)-ol]-enkephalin (0.5 µg) or κ-opioid receptor agonist bremazocine (4 µg). CONCLUSIONS: These data provide evidence for the involvement of CaCCs in δ-opioid receptor-induced central antinociception resulting from receptor activation by the agonist SNC80. CaCC activation does not appear to be involved when µ- and κ-opioid receptors are activated.


Assuntos
Analgésicos Opioides/farmacologia , Benzamidas/farmacologia , Cálcio/metabolismo , Canais de Cloreto/metabolismo , Dor/tratamento farmacológico , Piperazinas/farmacologia , Receptores Opioides delta/agonistas , Analgésicos Opioides/uso terapêutico , Animais , Benzamidas/uso terapêutico , Benzomorfanos/farmacologia , Cátions/metabolismo , Encefalinas/farmacologia , Temperatura Alta , Masculino , Camundongos , Camundongos Endogâmicos , Ácido Niflúmico/farmacologia , Dor/metabolismo , Limiar da Dor/efeitos dos fármacos , Piperazinas/uso terapêutico , Receptores Opioides kappa/agonistas , Receptores Opioides mu/agonistas
6.
Odontol. clín.-cient ; 11(1): 71-74, Jan.-Mar. 2012. ilus
Artigo em Inglês | LILACS | ID: lil-699750

RESUMO

Os mastócitos desempenham um importante papel em uma variedade de processos biológicos e participam, ativamente, da resposta inflamatória. Existe, no entanto, uma controvérsia na literatura a respeito da presença de mastócitos em polpas dentais. O presente trabalho procurou responder essa controvérsia no que se refere à presença de mastócitos no tecido pulpar de ratos e humanos em condições normais e durante a inflamação. Para isso, polpas inflamadas e não inflamadas de humanos e ratos foram coletadas e analisadas, utilizando-se a técnica histoquímica do azul de toluidina e a técnica de imunohistoquímica. Nossos resultados mostraram a ausência de mastócitos em polpas dentais de ratos e humanos tanto em condições normais quanto durante a inflamação. O papel dos mastócitos na resposta inflamatória da polpa dental não é claro. Fatores de crescimento e citocinas envolvidas na sua migração, desenvolvimento e sobrevivência podem estar ausentes no tecido pulpar e necessitam de futuras investigações.


Mast cells play an important role in a variety of biological processes and actively participate in the inflammatory response. There is a controversy in the literature whether mast cells are present in dental pulp. In this investigation we sought to answer the question concerning the presence of mast cells in human and rat dental pulp tissues, under normal and inflammatory conditions. Human and rat dental pulp under normal and inflammatory conditions were analyzed using toluidine blue histochemistry and immunohistochemistry techniques. Our results showed that inflamed and non-inflamed dental pulps neither from humans nor from rats presented mast cells. The role of mast cells in the inflammatory dental pulp response is not clear. Growth factors and cytokines involved in their migration, development and survival could be absent in this tissue and need further investigations.

7.
Eur J Pharmacol ; 674(2-3): 255-9, 2012 Jan 15.
Artigo em Inglês | MEDLINE | ID: mdl-22134006

RESUMO

Studies have demonstrated that the L-arginine/NO/cGMP pathway and the potassium and calcium channels are involved in the mechanisms underlying opioid receptor activation. As additional pathways may participate in the observed antinociceptive effects following opioid exposure, the aim of our study was to determine whether Ca(2+)-activated Cl(-) channels (CaCCs) are involved in peripheral antinociception induced by µ-, δ- and κ-opioid receptor activation. Hyperalgesia was induced by intraplantar injection of prostaglandin E(2) (PGE(2), 2 µg). Nociceptive thresholds to pressure (grams) were measured using an algesimetric apparatus 3h following injection. The µ-opioid receptor agonist morphine (200 µg), δ-opioid receptor agonist (+)-4-[(alphaR)-alpha-((2S,5R)-4-Allyl-2,5-dimethyl-1-piperazinyl)-3-methoxybenzyl]-N,N-diethylbenzamide (SNC80, 80 µg), κ-opioid receptor agonist bremazocine (50 µg), CaCCs blocker niflumic acid (8-64 µg), CaCCs blocker 5-Nitro-2-(3-phenylpropylamino) benzoic acid (NPPB, 32-128 µg), nitric oxide donor sodium nitroprusside (SNP, 500 µg) and cGMP exogenous analogs dibutyryl cGMP (db-cGMP, 100 µg) were also administered into the paw. The CaCCs blocker niflumic acid and NPPB partially reversed the peripheral antinociception induced by exposure to the SNC80 in a dose-dependent manner. In contrast, niflumic acid did not modify the antinociceptive effect observed following exposure to morphine or bremazocine. Additionally, the peripheral antinociception induced by the NO donor SNP or by db-cGMP was not inhibited by niflumic acid. These results provide evidence for the involvement of CaCCs in the peripheral antinociception induced by SNC80. CaCCs activation does not appear to be involved when µ- and κ-opioid receptors are activated. In addition, we did not observe a link between CaCCs and the L-arginine/NO/GMPc pathway.


Assuntos
Analgésicos/farmacologia , Canais de Cloreto/metabolismo , Sistema Nervoso Periférico/efeitos dos fármacos , Receptores Opioides delta/metabolismo , Analgésicos/antagonistas & inibidores , Animais , Arginina/metabolismo , Masculino , Ácido Niflúmico/farmacologia , Óxido Nítrico/metabolismo , Nitrobenzoatos/farmacologia , Nociceptividade/efeitos dos fármacos , Sistema Nervoso Periférico/citologia , Sistema Nervoso Periférico/metabolismo , Ratos , Ratos Wistar , Receptores Opioides delta/agonistas , Receptores Opioides kappa/metabolismo , Receptores Opioides mu/metabolismo , Transdução de Sinais/efeitos dos fármacos
8.
Arch Oral Biol ; 56(6): 540-8, 2011 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-21146808

RESUMO

OBJECTIVE: The beneficial effects of kappa opioid agonist U-50,488 in preventing periodontal disease (PD) progression in rats have already been described, but its mechanism of action is unknown. The present study evaluated the expression of TNF-α, IL-6, IL-8 and IL-10 in the gingival tissues of rats with ligature-induced PD, treated with U-50,488. It also correlated the effects of this agonist with myeloperoxidase (MPO) activity and the presence of osteoclasts. DESIGN: Male Holtzman rats weighing 250-300 g were divided into four groups: (1) control, (2) ligature, (3) ligature+saline and (4) ligature+kappa agonist. Experimental PD was induced by placing a sterile silk ligature around the 2nd left upper molar. Rats from groups 3 to 4 were locally administered with either saline or U-50,488, respectively, from day 3 to day 5 following ligation. After 5 or 11 days, the rats were euthanized and periodontal tissue samples were collected for histological and morphometric analysis and for determination of TNF-α, IL-6, IL-8, IL-10 and MPO. RESULTS: Ligature placement induced significant alveolar bone loss. The number of osteoclasts, degree of MPO activity, IL-6, IL-8 and TNF-α expression were also increased by PD. U-50,488 reduced both bone loss and the number of osteoclasts, but did not alter histological inflammatory infiltrate or MPO activity. U-50,488 significantly reduced IL-6 and increased IL-10 levels, but did not affect TNF-α and IL-8. CONCLUSION: Lowering the levels of IL-6 and increasing IL-10 are important mechanisms by which U-50,488 reduces alveolar bone loss in ligature-induced periodontal disease.


Assuntos
(trans)-Isômero de 3,4-dicloro-N-metil-N-(2-(1-pirrolidinil)-ciclo-hexil)-benzenoacetamida/farmacologia , Perda do Osso Alveolar/prevenção & controle , Interleucina-10/agonistas , Interleucina-6/antagonistas & inibidores , Receptores Opioides kappa/agonistas , Análise de Variância , Animais , Modelos Animais de Doenças , Interleucina-8/antagonistas & inibidores , Masculino , Osteoclastos/efeitos dos fármacos , Peroxidase/antagonistas & inibidores , Ratos , Ratos Sprague-Dawley , Fator de Necrose Tumoral alfa/antagonistas & inibidores
9.
Appl Radiat Isot ; 68(12): 2261-7, 2010 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-20579894

RESUMO

AIM: The aim of this study was to evaluate early detection of temporomandibular joint (TMJ) inflammatory changes based on 1-thio-beta-d-glucose radiolabeled with technetium-99m. METHOD: The method applied a TMJ inflammation model in rats followed by radiopharmaceutical synthesis, intravenous administration of (99m)Tc-1-TG and kinetic scintigraphy imaging. RESULTS: Results show a significant difference of (99m)Tc-1-TG uptake between inflamed TMJ and the control joint. The biodistribution of (99m)Tc-1-TG by images showed the kidneys' excretion. CONCLUSION: As conclusion, (99m)Tc-1-TG is a helpful tool in TMJ inflammatory process detection.


Assuntos
Glucose/administração & dosagem , Compostos de Organotecnécio , Compostos Radiofarmacêuticos , Transtornos da Articulação Temporomandibular/diagnóstico , Animais , Glucose/química , Masculino , Ratos
10.
Br J Pharmacol ; 158(1): 225-31, 2009 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-19594755

RESUMO

BACKGROUND AND PURPOSE: It has been demonstrated that cannabinoids evoke the release of endogenous opioids to produce antinociception; however, no information exists regarding the participation of cannabinoids in the antinociceptive mechanisms of opioids. The aim of the present study was to determine whether endocannabinoids are involved in central antinociception induced by activation of mu-, delta- and kappa-opioid receptors. EXPERIMENTAL APPROACH: Nociceptive threshold to thermal stimulation was measured according to the tail-flick test in Swiss mice. Morphine (5 microg), SNC80 (4 microg), bremazocine (4 microg), AM251 (2 and 4 microg), AM630 (2 and 4 microg) and MAFP (0.1 and 0.4 microg) were administered by the intracerebroventricular route. KEY RESULTS: The CB(1)-selective cannabinoid receptor antagonist AM251 completely reversed the central antinociception induced by morphine in a dose-dependent manner. In contrast, the CB(2)-selective cannabinoid receptor antagonist AM630 did not antagonize this effect. Additionally, the administration of the anandamide amidase inhibitor, MAFP, significantly enhanced the antinociception induced by morphine. In contrast, the antinociceptive effects of delta- and kappa-opioid receptor agonists were not affected by the cannabinoid antagonists. The antagonists alone caused no hyperalgesic or antinociceptive effects. CONCLUSIONS AND IMPLICATIONS: The results provide evidence for the involvement of cannabinoid CB(1) receptors in the central antinociception induced by activation of mu-opioid receptors by the agonist morphine. The release of endocannabinoids appears not to be involved in central antinociception induced by activation of kappa- and delta-opioid receptors.


Assuntos
Morfina/farmacologia , Medição da Dor/efeitos dos fármacos , Receptor CB1 de Canabinoide/fisiologia , Receptores Opioides delta/fisiologia , Receptores Opioides kappa/fisiologia , Receptores Opioides mu/fisiologia , Analgésicos Opioides/farmacologia , Animais , Indóis/farmacologia , Masculino , Camundongos , Medição da Dor/métodos , Piperidinas/farmacologia , Pirazóis/farmacologia , Receptores Opioides delta/metabolismo , Receptores Opioides kappa/metabolismo , Receptores Opioides mu/agonistas
11.
Mediators Inflamm ; 2009: 760837, 2009.
Artigo em Inglês | MEDLINE | ID: mdl-20069116

RESUMO

The study aimed to evaluate the suitability of myeloperoxidase (MPO) content as a local indicator of chronic inflammation, using the periodontal disease model. Anesthetized adult male Holtzman rats had their second left maxilar molar tied by a thread for 11 days and were then killed. Blood samples and photographic images from histopathological inflamed and noninflamed (contralateral) neighboring gingivomucosal specimens were collected for cell counts and MPO level analysis. Diseased animals were also treated with pharmacological tools such as the anti-inflammatory drug celecoxib or the opioid morphine. Increased blood neutrophils and local cell numbers characterized diseased animals. However, local MPO content was increased in inflamed and noninflamed tissues from diseased animals. Celecoxib and morphine reduced blood neutrophils and bilateral MPO content, but only celecoxib reduced local cell numbers in diseased animals. It is concluded that MPO content is a good indicator of a systemic rather than a local inflammation in a chronic inflammatory condition.


Assuntos
Biomarcadores/metabolismo , Inflamação/metabolismo , Doenças Periodontais/metabolismo , Peroxidase/metabolismo , Animais , Anti-Inflamatórios/uso terapêutico , Celecoxib , Contagem de Leucócitos , Masculino , Morfina/uso terapêutico , Neutrófilos/citologia , Neutrófilos/efeitos dos fármacos , Doenças Periodontais/tratamento farmacológico , Doenças Periodontais/patologia , Pirazóis/uso terapêutico , Ratos , Sulfonamidas/uso terapêutico
12.
Arq. odontol ; 43(1): 19-22, 2007. ilus
Artigo em Inglês | LILACS, BBO - Odontologia | ID: lil-518046

RESUMO

Apical root resorption is a common outcome of orthodontic treatment. The present article reports a case of absence of apical root resorption in a left maxillary lateral incisor filled with calcium hydroxide paste throughout orthodontic movement. After orthodontic treatment was completed the tooth was subsequently obturated with gutta-percha and the patient followed for 18 months. The presence of a periapical lesion and the properties of calcium hydroxide as a root resorption inhibitor were decisive for such an approach in the presented case. Also, the role played by the vital dental pulp in the resorptive process was discussed.


Assuntos
Feminino , Adulto , Ortodontia/tendências , Tratamento do Canal Radicular/tendências , Guta-Percha/uso terapêutico , Hidróxido de Cálcio/uso terapêutico , Reabsorção da Raiz
13.
Rev. Assoc. Paul. Cir. Dent ; 56(1): 57-61, jan.-fev. 2002. tab, graf
Artigo em Português | LILACS, BBO - Odontologia | ID: lil-308425

RESUMO

O objetivo deste estudo foi avaliar os efeitos do verniz com flúor Duraphat na prevençäo da cárie e na remineralizaçäo de lesöes de mancha branca ativa em pacientes com paralisia cerebral. Neste trabalho, foram selecionados trinta e cinco indivíduos de oito a dezoito anos, que foram divididos em dois grupos: teste e controle. Realizaram-se duas aplicaçöes do verniz Duraphat em dentes decíduos e permanentes totalmente erupcionados, com intervalo de 5 meses, e os resultados clínicos obtidos foram submetidos à análise estatística. Nesta pesquisa, concluímos que a aplicaçäo do verniz com flúor Duraphat foi eficaz na prevençäo da cárie e na reminralizaçäo de lesöes de mancha branca ativa e que o intervalo das suas aplicaçöes foi considerado muito longo em pacientes com paralisia cerebral


Assuntos
Humanos , Masculino , Feminino , Criança , Adolescente , Adulto , Cárie Dentária/prevenção & controle , Paralisia Cerebral , Fluoretos Tópicos/farmacologia
14.
Recurso educacional aberto em Português | CVSP - Brasil | ID: una-8811

RESUMO

Esta webaula contém informações sobre o que muda no atendimento odontológico a pacientes portadores de patologias crônicas não transmissíveis, principalmente hipertensão arterial sistêmica e diabetes mellitus.


Assuntos
Odontologia , Diabetes Mellitus , Hipertensão
15.
Recurso educacional aberto em Português | CVSP - Brasil | ID: una-9819

RESUMO

Esta webaula aborda o uso profilático de antibióticos em Odontologia.


Assuntos
Odontologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA